<DOC>
	<DOC>NCT02630680</DOC>
	<brief_summary>The purpose of the study is to assess Eziclen/Izinova drug utilisation in the real life setting in a representative sample of the European target population.</brief_summary>
	<brief_title>Eziclen Drug Utilisation in Real Life Setting</brief_title>
	<detailed_description />
	<criteria>Patient eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation. Patient having provided written informed consent. Patient not eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation. Specifically, patients in whom there is a contraindication for use of this product, including patients with congestive heart failure, severe renal insufficiency of active inflammatory bowel disease, are not eligible for inclusion in this study. Patient being prescribed a cleansing bowel preparation other than BLI800 (Eziclen®/Izinova®).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>